Safety and Tolerability of Oral Cannabinoids in People Living with HIV on Long-Term ART: A Randomized, Open-Label, Interventional Pilot Clinical Trial (CTNPT 028)
Authors:
- Ralph-Sydney Mboumba BouassaRBRalph-Sydney Mboumba Bouassa
- Judy NeedhamJNJudy Needham
- Dana NohynekDNDana Nohynek
- Joel SingerJSJoel Singer
- Terry LeeTLTerry Lee
- Florian BobeufFBFlorian Bobeuf
- Suzanne SamaraniSSSuzanne Samarani
- Lina Del BalsoLBLina Del Balso
- Natalie PaisibleNPNatalie Paisible
- Claude VertzagiasCVClaude Vertzagias
- Giada SebastianiGiada Sebastiani
- Shari MargoleseSMShari Margolese
Open Access
- 7 December 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (12) , 3168
Abstract
Background: With anti-inflammatory properties, cannabinoids may be a potential strategy to reduce immune activation in people living with HIV (PLWH) but more information on their safety and tolerability is needed. Methods: We conducted an open-label interventional pilot study at the McGill University Health Centre in Montreal, Canada. PLWH were randomized to oral Δ9-tetrahydrocannabinol (THC): cannabidiol (CBD) combination (THC 2.5 mg/CBD 2.5 mg) or CBD-only capsules (CBD 200 mg). Individuals titrated doses as tolerated to a maximum daily dose THC 15 mg/CBD 15 mg or 800 mg CBD, respectively, for 12 weeks. The primary outcome was the percentage of participants without any significant toxicity based on the WHO toxicity scale (Grades 0–2 scores). Results: Out of ten individuals, eight completed the study. Two from the CBD-only arm were withdrawn for safety concerns: phlebotomy aggravating pre-existing anemia and severe hepatitis on 800 mg CBD with newly discovered pancreatic adenocarcinoma, respectively. Seven did not have any significant toxicity. Cannabinoids did not alter hematology/biochemistry profiles. CD4 count, CD4/CD8 ratio, and HIV suppression remained stable. Most adverse effects were mild-moderate. Conclusions: In PLWH, cannabinoids seem generally safe and well-tolerated, though larger studies are needed. Screening for occult liver pathology should be performed and hepatic enzymes monitored, especially with high CBD doses.Keywords
Funding Information
- Canadian Institutes of Health Research (CC1-177334)
- CIHR Canadian HIV Trials Network and the Lotte & John Hecht Memorial Foundation
- FRSQ-S Chercheur Boursier Clinicien Senior (296306)
This publication has 72 references indexed in Scilit:
- Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetesNature Medicine, 2013
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaTranslational Psychiatry, 2012
- Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) IIIBMJ Open, 2012
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Persistent Microbial Translocation and Immune Activation in HIV‐1–Infected South Africans Receiving Combination Antiretroviral TherapyThe Journal of Infectious Diseases, 2010
- Cannabinoids, Endocannabinoids, and Related Analogs in InflammationThe AAPS Journal, 2009
- Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical TrialNeuropsychopharmacology, 2008
- Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trialPain, 2007
- Barriers to access to medical cannabis for Canadians living with HIV/AIDSAIDS Care, 2007
- Medicinal and Recreational Marijuana Use by Patients Infected with HIVAIDS Patient Care and STDs, 2004